Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Cand5 enters phase I study for AMD

Oct. 14, 2004

Photrex chosen as new brand name for SnET2

Oct. 11, 2004

Squalamine granted fast track status for wet AMD

Oct. 7, 2004

Therapeutic benefits of omalizumab in allergy conjunctivitis

Oct. 6, 2004

Approvable letter for SnET2 for AMD

Oct. 5, 2004

ISTA and Allergan sign new Vitrase agreement

Oct. 4, 2004

Expanded phase II trial for squalamine opens enrollment

Oct. 1, 2004

ISTA Pharmaceuticals' Vitrase granted three-year market exclusivity

Sep. 23, 2004

The EMEA accepts marketing authorization application for Macugen

Sep. 23, 2004

Approvable letter for Extravan for glaucoma

Sep. 21, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...